Journal Article Review Ppublish 1 citation
PubMed: 39690057 DOI: 10.1016/j.molmed.2024.11.012
New therapeutic approaches for fibrosis: harnessing translational regulation.
Trends Mol Med 31(7):640-651
Authors: Sumeen Kaur Gill, Richard H Gomer
Affiliations
- Department of Biology, Texas A&M University, College Station, TX, USA.
- Department of Biology, Texas A&M University, College Station, TX, USA.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating lung disease characterized by excessive extracellular matrix deposition and tissue scarring. The median survival of patients with IPF is only 4.5 years following diagnosis, and effective treatment options are scarce. Recent studies found aberrant translation of specific mRNAs in various fibrosing diseases, highlighting the role of key translational regulators, including RNA binding proteins (RBPs), microRNAs, long noncoding RNAs, and transcript modifications. Notably, when inhibited, 10 profibrotic RBPs cause a significant attenuation of fibrosis, illuminating potential therapeutic targets. In this review, we describe translational regulation in fibrosis and highlight a model where a conserved evolutionary mechanism may explain this regulation.
MeSH
Idiopathic Pulmonary Fibrosis, Fibrosis, Molecular Biology, Therapeutics